Logo_Biofrontera_AG.png
Biofrontera to Present at Two Upcoming Investor Conferences
June 12, 2019 10:58 ET | Biofrontera AG
Leverkusen, Germany, June 12, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Logo_Biofrontera_AG.png
Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
May 16, 2019 04:30 ET | Biofrontera AG
Leverkusen, Germany, May 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo_Biofrontera_AG.png
Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
April 16, 2019 07:30 ET | Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Logo_Biofrontera_AG.png
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
March 25, 2019 10:00 ET | Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...
Logo_Biofrontera_AG.png
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
March 20, 2019 10:50 ET | Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...
Logo_Biofrontera_AG.png
Biofrontera Honored with Prestigious Silver Stevie(R) Award for Outstanding U.S. Customer Service Department of the Year
February 25, 2019 09:30 ET | Biofrontera AG
Leverkusen, Germany, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that...
Logo_Biofrontera_AG.png
Ruling by the U.S. District Court of Massachussetts
December 27, 2018 15:31 ET | Biofrontera AG
Leverkusen, Germany, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today comments on a...
Logo_Biofrontera_AG.png
Biofrontera to Present at the 4th Annual Dawson James Small Cap Growth Stock Conference
October 15, 2018 04:19 ET | Biofrontera AG
Leverkusen, Germany, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann...
Logo_Biofrontera_AG.png
Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland
October 01, 2018 09:08 ET | Biofrontera AG
Leverkusen, Germany, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the...
Logo_Biofrontera_AG.png
Biofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference
September 24, 2018 07:44 ET | Biofrontera AG
Leverkusen, Germany, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Thomas...